How Is Retatrutide Taken? Dosage Schedule, Trial Data & What to Expect

Retatrutide is making headlines for a reason. In Phase 3 trials, it produced an average body weight loss of up to 28.7% at 68 weeks. That is more than any approved weight loss drug has ever achieved. If you want to know how to take retatrutide, what dose is used, and how the schedule works, this guide covers it all.

Everything here is based on published clinical trial data and Eli Lilly’s official Phase 3 TRIUMPH announcements. No speculation. No community anecdote. Just the numbers.

What Is Retatrutide, And Why Does It Work So Well?

Retatrutide is a triple hormone receptor agonist. It targets three receptors in the body at once:

• GLP-1 receptor
• GIP receptor
• Glucagon receptor

Most weight loss drugs you have heard of only target one or two receptors. Semaglutide (Wegovy, Ozempic) hits GLP-1 only. Tirzepatide (Mounjaro, Zepbound) targets both GLP-1 and GIP receptors. Retatrutide adds the glucagon receptor on top of both.

That third receptor, glucagon, is the key difference. It increases energy expenditure. In simple terms, it helps the body burn more stored fat. That is one reason the weight loss figures are so much higher.

Retatrutide is typically given as a subcutaneous injection once per week. It is currently being studied by Eli Lilly under the TRIUMPH Phase 3 clinical trial program. It is not yet FDA-approved. Access is limited to participants in clinical studies.

Retatrutide Dosage: What the Clinical Trials Actually Use

The most reliable source for retatrutide dosage data is the clinical trials themselves.

The Phase 2 trial (Jastreboff et al., NEJM 2023) tested four active dose groups: 1 mg, 4 mg, 8 mg, and 12 mg weekly.

The Phase 3 TRIUMPH program expanded this. It is now testing five doses: 2 mg, 4 mg, 6 mg, 9 mg, and 12 mg. The primary maintenance doses being studied are 4 mg, 9 mg, and 12 mg.

All doses are given as once-weekly injections under the skin. Every participant starts at 2 mg and increases every four weeks.

Phase 2 Trial Weight Loss Results (48 Weeks)

Phase 3 TRIUMPH-4 Results (68 Weeks), December 2025

In December 2025, Eli Lilly reported topline data from the Phase 3 TRIUMPH-4 trial. The results showed positive outcomes

This study represents the first Phase 3 trial to release results. Participants had obesity and knee osteoarthritis.

Nearly half of the participants on retatrutide achieved at least 25% weight loss. A meaningful subset exceeded 30%. These are numbers no approved obesity drug has matched.

Seven more Phase 3 studies are expected to publish results during 2026. Some analysts predict the 80-week TRIUMPH-1 trial could show weight loss exceeding 30%.

FDA approval is currently expected in 2027, pending successful Phase 3 results and regulatory review.

How Does the Retatrutide Dosing Schedule Work?

The dosing schedule is straightforward. But it is critical to follow it correctly.

Everyone starts at 2 mg per week. The dose increases every four weeks. This is called dose escalation or titration.

The reason for this slow ramp-up is simple. Your body needs time to adjust. Moving too fast causes severe nausea. Severe nausea leads most people to stop the medication. And stopping means zero weight loss.

Standard Retatrutide Titration Schedule (TRIUMPH Program)

Important: Not everyone needs to reach 12 mg. Many people achieve their goals at 9 mg or even 4 mg. Your prescriber will determine the right dose for your body.

What If You Experience Side Effects?

If side effects are troublesome, do not push through to the next dose. Stay at your current dose for an extra two to four weeks. Your body will usually adapt.

The biological and clinical factors that determine why some participants need longer at each dose tier are covered in detail in the 8 key retatrutide dose factors in clinical studies.

If nausea is severe, your prescriber may temporarily drop you back to the previous dose level. This is completely normal.

The goal is to find the highest dose you can tolerate comfortably while still getting good results. That number is different for everyone.

How to Read Your Retatrutide Dose: What the Numbers Mean

If you are enrolled in a clinical trial or discussing retatrutide with a prescriber, you will see doses written in milligrams (mg).

Here is a simple reference for the five doses used in the TRIUMPH trials:

These are the only doses that have been tested in clinical trials. There is no official data on doses above 12 mg or below 2 mg as a starting point.

For a step-by-step breakdown of how to convert these mg doses into the correct syringe volume, see the retatrutide dosing calculator guide.

How to Start Retatrutide: What You Need to Know Before Your First Dose

Before starting any trial medication, you need to understand a few things clearly.

You cannot buy Retatrutide

Retatrutide is not available at a pharmacy. It is not commercially sold. It is not FDA-approved.

At this time, clinical trial participation is the only way to receive retatrutide. You can find open trials at ClinicalTrials.gov.

Any product sold online as “retatrutide” is not the pharmaceutical-grade compound used in trials. The FDA has issued warnings that unapproved GLP-1 products sold online are not intended for human use and carry serious safety risks.

Who Is a Candidate for Retatrutide Trials?

Based on the TRIUMPH trial inclusion criteria, candidates typically include:

• Adults with obesity (BMI ≥30) may qualify. Those with overweight (BMI ≥27) may also be eligible if they have a related health condition.
• Adults with type 2 diabetes are being studied in separate trial arms
• Adults with specific comorbidities, including knee osteoarthritis or sleep apnea (in dedicated trials)

Exclusion criteria generally include a personal or family history of medullary thyroid carcinoma, pancreatitis, and certain cardiovascular conditions. A prescriber or trial coordinator reviews your full medical history before enrollment.

What Happens at Each Dose Level: Week by Week

What Clinical Trials Reveal About Retatrutide Side Effects

Side effects are real. But most are manageable when the dose is escalated correctly.

The most common side effects seen in the Phase 2 and Phase 3 trials were gastrointestinal. These include:

• Nausea is commonly reported, especially during dose escalation.
• Diarrhea
• Vomiting
• Constipation
• Decreased appetite (this is also the intended effect)

Most participants rated these effects as mild to moderate. They were most noticeable when the dose was being increased. Once the dose stabilised, patients generally saw a significant reduction.

Serious adverse events were rare. They occurred at similar rates in both the retatrutide and placebo groups in the Phase 2 trial.

Heart Rate:

One effect that is worth knowing about: retatrutide can increase resting heart rate. This is due to the glucagon receptor component. In the Phase 2 trial, heart rate increases peaked around week 24 and then declined. Cardiovascular monitoring was part of the trial protocol.

Hair Loss:

Some participants reported temporary hair thinning. This is a well-known response to rapid weight loss in general. This effect is not directly caused by the compound itself. It typically resolves on its own.

How to Reduce Side Effects?

The single most effective strategy is slow escalation. Do not rush to higher doses. Other practical steps include:

• Inject at night so you sleep through the peak nausea window
• Eat smaller, lower-fat meals
• Stay well hydrated
• Maintain adequate protein intake
• If nausea is severe, discuss anti-nausea options with your prescriber

Retatrutide vs Semaglutide vs Tirzepatide: How the Dosage and Results Compare

It helps to put retatrutide’s numbers in context. Here is how it stacks up against the two leading approved weight loss drugs.

Retatrutide produced more weight loss, faster. That is the straightforward reading of the data.

However, semaglutide and tirzepatide are FDA-approved and commercially available. Retatrutide is not. If you need medication now, those are your current options.

If you are waiting for retatrutide approval, FDA review is expected to begin in late 2026 or 2027, following the completion of remaining Phase 3 trials.

Questions to Ask Your Doctor About Retatrutide Dosage. 

More people are asking their doctors about retatrutide. That is a good thing. But walking into that conversation makes a big difference.

Here is how to approach it.

Step 1: Know What Stage It Is At

Tell your doctor that retatrutide is currently in Phase 3 clinical trials. The first Phase 3 results (TRIUMPH-4) were released in December 2025, showing 28.7% weight loss at 68 weeks. Seven additional trials are expected to report in 2026.

FDA approval is anticipated in 2027. It is not available by prescription yet.

Step 2: Ask About Clinical Trial Eligibility

The TRIUMPH trial program is ongoing. Ask your doctor if you might qualify for enrollment. You can also search ClinicalTrials.gov using the term “retatrutide” to find open studies near you.

Step 3: Understand the Dosing Commitment

Retatrutide requires weekly injections. Dosing typically begins at 2 mg and is increased every four weeks. Reaching the full therapeutic dose takes around four to five months. This is a long-term commitment, not a short course.

Ask your doctor if this kind of protocol fits your lifestyle and health situation.

Step 4: Discuss Your Medical History Honestly

Be open about your full medical history. Some medical conditions may affect whether retatrutide is appropriate. These include thyroid disorders, cardiovascular disease, or a history of pancreatitis.

Your doctor needs the full picture to advise you properly.

Step 5: Do Not Self-Medicate

This point cannot be overstated. Do not attempt to source or self-administer any compound sold as retatrutide online. The FDA has been clear that such products are unregulated, potentially dangerous, and not the pharmaceutical compound used in trials.

The results in clinical trials came from a controlled environment with medical supervision. Self-administration removes every safety layer that produced those results.

Frequently Asked Questions About Retatrutide Dosage

The Bottom Line

Retatrutide is the most effective weight loss drug ever studied in clinical trials.

The Phase 3 data is real. The 28.7% average weight loss figure is based on a 68-week trial of over 400 participants.

The dosing protocol is clear. Start at 2 mg. Increase every four weeks. The available maintenance doses being tested are 4 mg, 9 mg, and 12 mg.

But the key point is this: retatrutide is not yet available. The road to FDA approval runs through the rest of the TRIUMPH trial program and a formal regulatory review process. That process is expected to be completed in 2027.

Use this guide to understand the science. This can help you ask the right questions during medical appointments. And wait for the legitimate, supervised path to this medication, because the trial results show that path is worth it.

References

Phase 2 Clinical Trial: Peer-Reviewed

1. Jastreboff AM, Kaplan LM, Frías JP, et al. Retatrutide, a triple-hormone receptor agonist, was studied in a Phase 2 trial for obesity. New England Journal of Medicine.

Phase 3 TRIUMPH-4: Official Eli Lilly Announcements

2. Eli Lilly and Company. In its first Phase 3 trial, Lilly’s retatrutide led to an average weight loss of up to 71.2 lbs. Participants also experienced notable improvement in osteoarthritis pain. Press release. December 11, 2025.
3. Eli Lilly and Company. TRIUMPH-4 Phase 3 Trial Full Press Release via PR Newswire. December 11, 2025.